Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Relay Therapeutics ( (RLAY) ) just unveiled an update.
On March 6, 2026, Relay Therapeutics, Inc. amended and restated its bylaws to specify that federal district courts in the United States will serve as the exclusive forum for complaints arising under the Securities Act of 1933 and the Securities Exchange Act of 1934, along with related rules and regulations. The move centralizes securities-related litigation in federal courts, potentially reducing jurisdictional disputes, increasing procedural predictability for the company and investors, and aligning Relay Therapeutics with a growing governance trend among U.S. public companies.
The most recent analyst rating on (RLAY) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on Relay Therapeutics stock, see the RLAY Stock Forecast page.
Spark’s Take on RLAY Stock
According to Spark, TipRanks’ AI Analyst, RLAY is a Neutral.
The score is held back primarily by weak financial performance (large ongoing losses and cash burn), partly offset by strong technical momentum (price above key moving averages with positive MACD) and a supportive corporate catalyst (FDA Breakthrough Therapy designation). Valuation remains difficult to assess due to negative earnings and no indicated dividend yield.
To see Spark’s full report on RLAY stock, click here.
More about Relay Therapeutics
Relay Therapeutics, Inc. is a biotechnology company focused on discovering and developing precision medicines, leveraging insights into protein motion to design targeted therapies for cancer and other serious diseases within the biopharmaceutical sector.
Average Trading Volume: 2,401,655
Technical Sentiment Signal: Buy
Current Market Cap: $1.91B
For a thorough assessment of RLAY stock, go to TipRanks’ Stock Analysis page.